Juluca (Dolutegravir + rilpivirine)
dolutegravir 50 mg + rilpivirine 25 mg tablet, 30 · ORAL · PBS code 11540J
STREAMLINEDWhat it costs
AU$800.31 PBS-determined price per 60 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2018-12-01.
- • Repeats: 5.
- • PBS program: CA.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
HIV infection
Initial treatment
Patient must be virologically suppressed on a stable antiretroviral regimen for at least 6 months; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
HIV infection
Continuing treatment
Patient must have previously received PBS-subsidised therapy with this drug for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
Sponsor: ViiV Healthcare Pty Ltd ABN 46 138 687 448
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.